10-Day Rally Sends Haemonetics Stock Up 48%
Haemonetics (HAE) stock hit day 10 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 48% return. The company has gained about $1.1 Bil in value over the last 10 days, with its current market capitalization at about $3.5 Bil. The stock remains 6.4% below its value at the end of 2024. This compares with year-to-date returns of 16.5% for the S&P 500.
Haemonetics’ recent streak was ignited by a stellar Q2 earnings beat, showcasing impressive organic growth and margin expansion. An upgraded full-year outlook, driven by plasma market gains and strategic product rollouts, bolstered investor enthusiasm.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There are a few things to fear in HAE stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced (see Buy or Sell HAE). Nevertheless, individual stocks can soar or tank but one thing matters: staying invested. High Quality Portfolio helps you do that.
For quick background, HAE provides medical products and solutions, including automated plasma collection devices, blood component systems, disposables, and related software across plasma, blood center, and hospital segments.
- Broadcom Stock Down 21%,Time to Buy?
- Ambarella Stock To $49?
- Would You Still Hold Southwest Airlines Stock If It Fell 30%?
- Would You Still Hold Palantir Technologies Stock If It Fell Another 30%?
- With Lam Research Stock Sliding, Have You Assessed The Risk?
- Is Fluence Energy Stock Built to Withstand More Downside?
Comparing HAE Stock Returns With The S&P 500
The following table summarizes the return for HAE stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | HAE | S&P 500 |
|---|---|---|
| 1D | 1.9% | 0.1% |
| 10D (Current Streak) | 47.9% | -0.6% |
| 1M (21D) | 46.9% | 3.1% |
| 3M (63D) | 39.7% | 5.9% |
| YTD 2025 | -6.4% | 16.5% |
| 2024 | -8.7% | 23.3% |
| 2023 | 8.7% | 24.2% |
| 2022 | 48.3% | -19.4% |
However, big gains can follow sharp reversals – but how has HAE behaved after prior drops? See HAE Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 113 S&P constituents with 3 days or more of consecutive gains and 13.0 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 30 | 13 |
| 4D | 47 | 0 |
| 5D | 17 | 0 |
| 6D | 11 | 0 |
| 7D or more | 8 | 0 |
| Total >=3 D | 113 | 13 |
Key Financials for Haemonetics (HAE)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $1.3 Bil | $1.4 Bil |
| Operating Income | $173.3 Mil | $201.2 Mil |
| Net Income | $117.6 Mil | $167.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2026 FQ1 | 2026 FQ2 |
|---|---|---|
| Revenues | $321.4 Mil | $327.3 Mil |
| Operating Income | $53.9 Mil | $67.1 Mil |
| Net Income | $34.0 Mil | $38.7 Mil |
While HAE stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.